Precision-Engineered CD3 T-Cell Engagers for Solid Tumours: Conditional Activation, Microenvironment Modulation, and Clinical Translation

Cancers 2026 Open access

Read full text
Authors: Md. Zeyaullah, Abdullah M. AlShahrani, Mohammad Suhail Khan, Md Faruque Ahmad, Abdelrhman A. G. Altijani, Awad Osman Abdalla Mohamed, Hytham Hummad, Ali Mohieldin, S. Rehan Ahmad
DOI: 10.3390/cancers18071088
Cited by: 3
References: 88

Abstract

BACKGROUND: T-cell-engaging bispecific antibodies (TCEs) have transformed haematological malignancy treatment (blinatumomab > 40% complete remission), yet solid tumour efficacy remains limited (

Fields of Study & Subjects

Monoclonal and Polyclonal Antibodies Research CAR-T cell therapy research vaccines and immunoinformatics approaches

Publication details

Journal / source
Cancers
Publisher
MDPI AG
Volume
18
Issue
7
Pages
1088–1088
Publication date
27 March 2026
Language
EN